Letrozole Versus Clomifene Citrate for Ovulation Induction

This study is currently recruiting participants.

Verified by Derby Hospitals NHS Foundation Trust, May 2007

Sponsored by:	Derby Hospitals NHS Foundation Trust
Information provided by:	Derby Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier:	NCT00478504

Purpose

The primary aim of the study is to assess the efficacy of letrozole as an ovulation induction agent and to test the hypothesis that letrozole will generate better pregnancy rates with fewer multiple pregnancies and higher live birth rate than the current standard agent, clomifene citrate in anovular infertile women with polycystic ovarian syndrome.

Condition	Intervention	Phase
Infertility Polycystic Ovarian Syndrome	Drug: Letrozole Drug: Clomifene citrate	Phase IV

MedlinePlus related topics: Infertility

Drug Information available for: Citric acid Sodium Citrate Clomiphene citrate Clomiphene Enclomiphene Zuclomiphene Letrozole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Efficacy Study
Official Title:	Double Blind Cross-Over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome

Further study details as provided by Derby Hospitals NHS Foundation Trust:

Primary Outcome Measures:

Pregnancy rate

Secondary Outcome Measures:

1. Ovulation rate 2. Number of growing and mature follicles during treatment 3. Miscarriage rate 4. Live-birth rate 5. Multiple pregnancy rate 6. Endometrial thickness

Estimated Enrollment:	212
Study Start Date:	May 2007

Eligibility

Ages Eligible for Study:	18 Years to 39 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age: 18 - 39
BMI < 36
Infertility due to anovulation
PCOS: At least two of the following diagnostic criteria of:
1. Oligo/amenorrhoea
2. Hyperandrogenaemia: biochemical (testosterone ≥2.5 nmol/l or free androgen index (FAI) ≥ 5) or clinical (acne/hirsutism) evidence
3. USS evidence of PCO (either ≥12 follicles measuring 2-9 mm in diameter, or an ovarian volume of > 10 ml)
No recent (within 6 months) treatment for induction of ovulation
Normal semen analysis (WHO 1999)
Proven patency of at least one Fallopian tube

Exclusion Criteria:

Inability to give informed consent
Contraindication to letrozole or clomifene citrate
Absence of any inclusion criteria

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00478504

Contacts

Contact: Saad Amer, MD, MRCOG

+44(1332)724612

saad.amer@nottingham.ac.uk

Locations

United Kingdom, Derbyshire
Derby City General Hospital	Recruiting
Derby, Derbyshire, United Kingdom, DE22 3NE
Contact: Saad Amer, MD, MRCOG +44(1332)724612 saad.amer@nottingham.ac.uk

Sponsors and Collaborators

Derby Hospitals NHS Foundation Trust

Investigators

Principal Investigator:

Saad Amer, MD, MRCOG

University of Nottingham and Derby Hospitals NHS foundation Trust

More Information

Study ID Numbers:	RD-5103-015-06, EudraCT No: 2006-006514-15
Study First Received:	May 23, 2007
Last Updated:	May 23, 2007
ClinicalTrials.gov Identifier:	NCT00478504
Health Authority:	United Kingdom: Medicines and Healthcare Products Regulatory Agency; United Kingdom: Research Ethics Committee; United Kingdom: National Health Service

Keywords provided by Derby Hospitals NHS Foundation Trust:

anovulation
ovulation induction,
polycystic ovarian syndrome
clomifene citrate
letrozole

Study placed in the following topic categories:

Infertility
Gonadal Disorders
Citric Acid
Endocrine System Diseases
Clomiphene
Letrozole
Ovarian Diseases

Genital Diseases, Male
Cysts
Genital Diseases, Female
Polycystic Ovary Syndrome
Endocrinopathy
Anovulation
Ovarian Cysts

Additional relevant MeSH terms:

Estrogen Antagonists
Disease
Anticoagulants
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Hormone Antagonists
Physiological Effects of Drugs
Hematologic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Enzyme Inhibitors
Reproductive Control Agents
Selective Estrogen Receptor Modulators

Pharmacologic Actions
Adnexal Diseases
Estrogen Receptor Modulators
Neoplasms
Pathologic Processes
Fertility Agents, Female
Syndrome
Therapeutic Uses
Fertility Agents
Chelating Agents
Aromatase Inhibitors

ClinicalTrials.gov processed this record on January 16, 2009